'Get to Know' - Biointaxis

Biointaxis, a spin-off of the Germans Trias i Pujol Research Institute (IGTP), is dedicated to scientific and technical research aimed at developing and commercializing genomic treatments and technologies for neurological diseases. They are currently advancing on the BTX-101, a groundbreaking treatment for Friedreich's Ataxia-a severe neurological disorder with no current cure.
Know more about the development of this innovative gene therapy and the project behind it in this webinar, in English.
You can invest in Biointaxis here! ⤵️
capitalcell.co...
#friederichataxia
#genomictreatment
#neurologicaldiseases
#diseaseswithouttreatment
#neurodegenerativedisorder
#defectivemitochondrialprotein
#cardiacfunction
#investmentraise
#investmentopportunity
#biotechinvestment